Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children

Eurosurveillance

Volumn 20, Issue 24, 2015, Pages 1-20

  Li Kim Moy, J ^a,b   Yin, J K ^a,b   Rashid, H ^a   Khandaker, G ^a,b   King, C ^a,b   Wood, N ^a,b   Macartney, K K ^a,b   Jones, C ^a,b,c   Booy, R ^a,b,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED TRIVALENT INFLUENZA VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; INACTIVATED VACCINE;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; FEBRILE CONVULSION; FEVER; HUMAN; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; META ANALYSIS; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFANT; INFLUENZA, HUMAN; PRESCHOOL CHILD;

CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEVER; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; SEIZURES, FEBRILE; VACCINES, INACTIVATED;

EID: 84932640748     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.es2015.20.24.21159     Document Type: Article

References (76)

1. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355(1):31-40. http://dx.doi.org/10.1056/ NEJMoa054869 PMID:16822994
2. Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185(2):147-52. http://dx.doi. org/10.1086/338363 PMID:11807687
3. Sakkou Z, Stripeli F, Papadopoulos NG, Critselis E, Georgiou V, Mavrikou M, et al. Impact of influenza infection on children's hospital admissions during two seasons in Athens, Greece. Vaccine. 2011;29(6):1167-72. http://dx.doi.org/10.1016/j. vaccine.2010.12.014 PMID:21172380
4. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-40. http://dx.doi. org/10.1001/jama.292.11.1333 PMID:15367555
5. Advisory Committee on Immunization Practices (ACIP). Summary recommendations: Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices-(ACIP)-United States, 2013-14. Atlanta: Centers for Disease Control and Prevention; 2013 Available from: http://www.cdc.gov/flu/professionals/ acip/2013-summary-recommendations.htm
6. Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill. 2010;15(44):19700. PMID:21087586
7. The flu immunisation programme 2013/14-extension to children. London: Department of Health; 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/ attachment_data/file/225360/Children_s_flu_letter_2013.pdf
8. Flu (influenza) vaccine and children: what WA parents need to know. Perth: Department of Health Western Australia. [Accessed: Nov 2012]. Available from: http://www.health. wa.gov.au/flu/families_individuals/children.cfm
9. Therapeutic Goods Administration (TGA). Seasonal flu vaccine: Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children. Canberra: TGA; 2010 Available from: https://www.tga.gov.au/alert/ seasonal-flu-vaccine-overview-vaccine-regulation-and-safetymonitoring-and-investigation-adverse-events-following-2010-seasonal-influenza-vaccination-young-children
10. Mak DB, Carcione D, Joyce S, Tomlin S, Effler PV. Paediatric influenza vaccination program suspension: effect on childhood vaccine uptake. Aust N Z J Public Health. 2012;36(5):494-5. http://dx.doi.org/10.1111/j.1753-6405.2012.00925.xPMID:23025380
11. Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine. 2004;22(5-6):551-6. http://dx.doi. org/10.1016/j.vaccine.2003.09.007 PMID:14741143
12. US Food and Drug Administration (FDA). What is a serious adverse event? Silver Spring: FDA. [Accessed: Sep 2014]. Available from: http://www.fda.gov/safety/medwatch/ howtoreport/ucm053087.htm
13. Altmann M, Fiebig L, Soyka J, von Kries R, Dehnert M, Haas W. Severe cases of pandemic (H1N1) 2009 in children, Germany. Emerg Infect Dis. 2011;17(2):186-92. http://dx.doi.org/10.3201/ eid1702.101090 PMID:21291587
14. Effective Public Health Practice Project (EPHPP). Quality assessment tool for quantitative studies. Hamilton: EPHPP. [Accessed: Oct 2013]. Available from: http://www.ephpp.ca/ tools.html
15. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):iii-x, 1-173. http://dx.doi. org/10.3310/hta7270 PMID:14499048
16. Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respi Viruses. 2011;5(5):299-305. http://dx.doi. org/10.1111/j.1750-2659.2011.00229.x PMID:21668694
17. Agarwal R, Aggarwal AN, Gupta D. Role of noninvasive ventilation in acute lung injury/acute respiratory distress syndrome: a proportion meta-analysis. Respir Care. 2010;55(12):1653-60. PMID:21122173
18. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160-74. http://dx.doi.org/10.1016/ S1470-2045(11)70002-X PMID:21251875
19. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679-90. http://dx.doi.org/10.1001/jama.296.6.679PMID:16896111
20. Pal T, Permuth-Wey J, Kumar A, Sellers TA. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res. 2008;14(21):6847-54. http://dx.doi.org/10.1158/1078-0432. CCR-08-1387 PMID:18980979
21. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231-40. http://dx.doi. org/10.1182/blood-2008-07-167155 PMID:18945961
22. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6-to 23-month-old children. Pediatrics. 2005;115(4):1039-47. http:// dx.doi.org/10.1542/peds.2004-2373 PMID:15805382
23. Hu YM, Fang HH, Gao GH, Zhang XF, Zhang YJ, Zhu SW, et al. [Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine]. Zhonghua Liu Xing Bing Xue Za Zhi. 2005;26(7):503-6. Chinese. PMID:16335001
24. Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25(10):870-9. http://dx.doi. org/10.1097/01.inf.0000237829.66310.85 PMID:17006279
25. Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, et al. Influenza vaccine immunogenicity in 6-to 23-monthold children: are identical antigens necessary for priming? Pediatrics. 2006;118(3):e570-8. http://dx.doi.org/10.1542/ peds.2006-0198 PMID:16950948
26. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685-96. http:// dx.doi.org/10.1056/NEJMoa065368 PMID:17301299
27. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics. 2007;119(6):1076-82. http://dx.doi.org/10.1542/peds.2006-3176 PMID:17545373
28. Zhu FC, Zhou W, Pan H, Lu L, Gerez L, Nauta J, et al. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China. Vaccine. 2008;26(35):4579-84. http://dx.doi. org/10.1016/j.vaccine.2008.05.082 PMID:18602729
29. King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirusexpressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine. 2009;27(47):6589-94. http://dx.doi.org/10.1016/j. vaccine.2009.08.032 PMID:19716456
30. Marchisio P, Esposito S, Bianchini S, Dusi E, Fusi M, Nazzari E, et al. Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis media. Pediatr Infect Dis J. 2009;28(10):855-9. http:// dx.doi.org/10.1097/INF.0b013e3181a487b4 PMID:19564812
31. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28(7):563-71. http://dx.doi. org/10.1097/INF.0b013e31819d6394 PMID:19561422
32. Baxter R, Jeanfreau R, Block SL, Blatter M, Pichichero M, Jain VK, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J. 2010;29(10):924-30. http://dx.doi. org/10.1097/INF.0b013e3181e075be PMID:20431425
33. Cowling BJ, Ng S, Ma ESK, Cheng CKY, Wai W, Fang VJ, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis. 2010;51(12):1370-9. http://dx.doi. org/10.1086/657311 PMID:21067351
34. Esposito S, Marchisio P, Ansaldi F, Bianchini S, Pacei M, Baggi E, et al. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine. 2010;28(38):6137-44. http://dx.doi.org/10.1016/j. vaccine.2010.07.041 PMID:20670909
35. Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics. 2010;126(4):e762-70. http://dx.doi. org/10.1542/peds.2009-2628 PMID:20819892
36. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845-53. http://dx.doi.org/10.1093/infdis/jir436 PMID:21846636
37. Kang JH, Oh CE, Lee J, Lee SY, Cha SH, Kim DS, et al. Safety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy Korean children: a randomized, double-blinded, active-controlled, phase III study. J Korean Med Sci. 2011;26(11):1421-7. http://dx.doi.org/10.3346/ jkms.2011.26.11.1421 PMID:22065897
38. Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011;128(2):e276-89. http://dx.doi.org/10.1542/ peds.2010-2777 PMID:21768314
39. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365(15):1406-16. http://dx.doi.org/10.1056/NEJMoa1010331 PMID:21995388
40. Mitchell DK, Ruben FL, Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr Infect Dis J. 2005;24(10):925-7. http://dx.doi.org/10.1097/01.inf.0000180978.66362.d9 PMID:16220095
41. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006;118(3):e579-85. http://dx.doi.org/10.1542/peds.2006-0201 PMID:16950949
42. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194(8):1032-9. http:// dx.doi.org/10.1086/507309 PMID:16991077
43. Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children. Medicina (B Aires). 2007;67(4):351-9. PMID:17891930
44. Schmidt-Ott R, Schwarz T, Haase R, Sander H, Walther U, Fourneau M, et al. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine. 2007;26(1):32-40. http://dx.doi.org/10.1016/j.vaccine.2007.10.049 PMID:18022736
45. Chai WQ, Lu F, Chen CH. [Adverse reaction and immune effect of split influenza virus vaccine in humans in 2005 and 2006]. Chinese Journal of Biologicals. 2008;21(2):139-42. Chinese.
46. Künzi V, Dornseiff M, Horwath J, Hartmann K. Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27(8):1261-5. http://dx.doi.org/10.1016/j. vaccine.2008.12.008 PMID:19114080
47. Nolan T, Richmond PC, McVernon J, Skeljo MV, Hartel GF, Bennet J, et al. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respi Viruses. 2009;3(6):315-25. http://dx.doi. org/10.1111/j.1750-2659.2009.00108.x PMID:19903213
48. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009;27(45):6291-5. http://dx.doi. org/10.1016/j.vaccine.2009.02.004 PMID:19840662
49. Walter EB, Englund JA, Blatter M, Nyberg J, Ruben FL, Decker MD; GRC27 Study Team. Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study. Pediatr Infect Dis J. 2009;28(12):1099-104. http://dx.doi. org/10.1097/INF.0b013e3181b0c0ca PMID:19935270
50. Wang X, Liu Y, Zhao YW. [Clinical trial on safety of inactivated split influenza virus vaccine, Anflu in 2007-2008]. Zhongguo Yi Miao He Mian Yi. 2009;15(5):443-6. Chinese.
51. D'Angio CT, Heyne RJ, Duara S, Holmes LC, O'Shea TM, Wang H, et al. Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. Pediatr Infect Dis J. 2011;30(7):570-4. http://dx.doi. org/10.1097/INF.0b013e31820c1fdf PMID:21273938
52. Walker WT, de Whalley P, Andrews N, Oeser C, Casey M, Michaelis L, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin Infect Dis. 2012;54(5):661-9. http://dx.doi.org/10.1093/cid/ cir905 PMID:22267719
53. Lambert SB, Chuk LM, Nissen MD, Nolan TM, McVernon J, Booy R, et al. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. Influenza Other Respi Viruses. 2013;7(5):676-85. http://dx.doi.org/10.1111/irv.12107 PMID:23551933
54. Salleras L, Dominguez A, Pumarola T, Prat A, Marcos MA, Garrido P, et al. Low reactogenicity of the virosomal subunit influenza vaccine in healthy children without risk factors. Vacunas. 2009;10(4):113-7.
55. Goodman MJ, Nordin JD, Harper P, Defor T, Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics. 2006;117(5):e821-6. http://dx.doi. org/10.1542/peds.2005-2234 PMID:16651286
56. Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, et al.; Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296(16):1990-7. http://dx.doi.org/10.1001/ jama.296.16.1990 PMID:17062862
57. Glanz JM, Newcomer SR, Hambidge SJ, Daley MF, Narwaney KJ, Xu S, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011;165(8):749-55. http://dx.doi. org/10.1001/archpediatrics.2011.112 PMID:21810637
58. Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open. 2011;1(1):e000016. http://dx.doi.org/10.1136/ bmjopen-2010-000016 PMID:22021725
59. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012;30(11):2024-31. http://dx.doi.org/10.1016/j.vaccine.2012.01.027 PMID:22361304
60. Brady RC, Hu W, Houchin VG, Eder FS, Jackson KC, Hartel GF, et al. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children. Vaccine. 2014;32(52):7141-7. http://dx.doi.org/10.1016/j. vaccine.2014.10.024 PMID:25454878
61. Wood N, Sheppeard V, Cashman P, Palasanthiran P, Casacelli M, Cannings K, et al. Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr Infect Dis J. 2012;31(2):199-202. http://dx.doi. org/10.1097/INF.0b013e31823d5303 PMID:22094632
62. Petousis-Harris H, Poole T, Turner N, Reynolds G. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance. Vaccine. 2012;30(33):4945-52. http:// dx.doi.org/10.1016/j.vaccine.2012.05.052 PMID:22664224
63. Van Buynder PG, Frosst G, Van Buynder JL, Tremblay FW, Ross A, Jardine C, et al. Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination. Influenza Other Respi Viruses. 2013;7(2):184-90. http://dx.doi. org/10.1111/j.1750-2659.2012.00364.x PMID:22498052
64. European Medicines Agency (EMA). Withdrawal assessment report: Fluad Paediatric. Influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1. London: EMA; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Application_withdrawal_assessment_ report/2012/04/WC500126030.pdf
65. Sancho A, Melchiorri D, Abadie E; Committee for Medicinal Products for Human Use, European Medicines Agency. More on influenza vaccine in young children. N Engl J Med. 2012;366(26):2528-9, author reply 2528-9. http://dx.doi. org/10.1056/NEJMc1205643 PMID:22738111
66. Kaczmarek MC, Duong UT, Ware RS, Lambert SB, Kelly HA. The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: a comparison of published and unpublished studies. Vaccine. 2013; 31(46):5359-65. http://dx.doi.org/10.1016/j. vaccine.2013.09.005.
67. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(RR-8):1-57. PMID:9639369
68. Stockwell MS, Broder K, LaRussa P, Lewis P, Fernandez N, Sharma D, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr. 2014;168(3):211-9. http:// dx.doi.org/10.1001/jamapediatrics.2013.4469 PMID:24395025
69. CSL Biotherapies provides update on Fluvax investigation. Parkville: CSL Biotherapies; 2012. Available from: http://www. csl.com.au/s1/cs/auhq/1187378853299/news/1255929042869/ prdetail.htm
70. Maraskovsky E, Rockman S, Dyson A, Koernig S, Becher D, Morelli AB, et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Vaccine. 2012;30(51):7400-6. http://dx.doi.org/10.1016/j. vaccine.2012.09.083 PMID:23063831
71. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012;8:CD004879. PMID:22895945
72. European Medicines Agency (EMA). European Medicines Agency updates guidance for annual strain change of seasonal influenza vaccines. London: EMA; 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news_and_events/news/2014/02/news_detail_002019. jsp&mid=WC0b01ac058004d5c1
73. European Medicines Agency (EMA). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU London: EMA; 2014. Available from: http://www. ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2014/04/WC500165492.pdf
74. Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013;9(9):1978-88. http://dx.doi.org/10.4161/hv.25363 PMID:23782962
75. Frey SE, Bernstein DI, Gerber MA, Keyserling HL, Munoz FM, Winokur PL, et al. Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. J Infect Dis. 2012;206(6):828-37. http://dx.doi.org/10.1093/infdis/jis445 PMID:22802432
76. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. http://dx.doi.org/10.1371/journal. pmed.1000097 PMID:19621072